Company intelligence / Profile preview
DoriVac
- Ownership
- Private
- Development stage
- Other
Overview
DoriVac is a biotechnology company developing a modular DNA origami-based vaccine platform designed to transform cancer immunotherapy and infectious disease prevention. Spun out from the Wyss Institute at Harvard University, the company utilizes self-assembling DNA nanostructures to precisely control the spatial arrangement and stoichiometry of antigens and adjuvants. This nanoscopic precision allows for the optimized stimulation of dendritic cells, leading to robust T-cell responses and enhanced anti-tumor activity. The platform is highly versatile, enabling the rapid development of personalized cancer vaccines and broad-spectrum infectious disease candidates.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineNanoparticleDNA vaccineImmunotherapy
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on DoriVac.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DoriVac.